Full-Time

Mechatronics Engineer 2

Confirmed live in the last 24 hours

Ginkgo Bioworks

Ginkgo Bioworks

501-1,000 employees

Programs cells to produce custom organisms

Food & Agriculture
Biotechnology
Healthcare

Compensation Overview

$93kAnnually

+ Company Stock Awards

Junior, Mid

Oakland, CA, USA

This is a hybrid role requiring in-office presence.

Category
Mechanical Maintenance and Reliability Engineering
Robotics and Automation Engineering
Mechanical Engineering

You match the following Ginkgo Bioworks's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS in Mechanical, Mechatronics, Systems, Robotics engineering or equivalent
  • Relevant experience in 3 or more of the following areas: Laboratory automation systems and experimental workflow development, Project-based experience using an engineering 3D CAD software package, Experience with making both 2D and 3D parts, Basic knowledge of wiring circuits, Familiarity with PLC’s, safety circuits and safety sensors, power electronics
  • Systems engineering training or mindset with attention to detail
  • Ability to independently execute on tasks to complete project work, with strategic support from manager and other stakeholders
Responsibilities
  • Design and build infrastructure for automating high-throughput lab processes
  • Collaborate with biologists on automation equipment design and operation
  • Work with vendors to build understanding of needs and capabilities
Desired Qualifications
  • Familiarity with Lab Automation equipment fundamentals
  • Demonstrable fabrication experience or ‘workshop’ skills
  • Experience programming 6-axis robot trajectories

Ginkgo Bioworks specializes in biotechnology by using advanced cell programming technology to create custom organisms that can produce various products, including food ingredients, fragrances, and therapeutics. Their platform allows them to design and grow these organisms, effectively turning cells into small factories that generate valuable compounds. Ginkgo collaborates with a wide range of clients, such as companies in the food and beverage sector, pharmaceuticals, agriculture, and biosecurity, to develop tailored biological solutions. This collaborative approach sets them apart from competitors, as they focus on partnerships to drive innovation and ensure a steady revenue stream through service fees, milestone payments, and royalties. The company's goal is to be a leader in the biotechnology field by providing effective and customized solutions that meet the specific needs of their partners.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$1.5B

Headquarters

Boston, Massachusetts

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Universal Cells enhances iPSC-derived therapies, revolutionizing cancer treatment.
  • Ginkgo Automation's system accelerates biofuels research, supporting sustainable energy solutions.
  • Participation in ARPA-H's REACT program advances bioelectronic devices for chronic disease treatment.

What critics are saying

  • Increased competition from companies like Phytolon in natural food colors market.
  • Lesaffre's acquisition of Altar may impact Ginkgo's fermentation market growth.
  • Restructuring efforts could lead to operational disruptions and affect employee morale.

What makes Ginkgo Bioworks unique

  • Ginkgo Bioworks leverages advanced cell programming to create custom organisms for diverse industries.
  • The company collaborates with industry leaders like Moderna and Cronos Group for innovative solutions.
  • Ginkgo's platform supports biosecurity, pharmaceuticals, agriculture, and more, showcasing its versatility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited paid time off

Comprehensive health and parental leave benefits

Flexible work options

Commuter benefits

State-of-the-art labs, work spaces, and conference rooms

Competitive 401K contribution

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

3%

2 year growth

2%
PR Newswire
Feb 6th, 2025
Ginkgo Bioworks To Host 6Th Annual Ferment As Boston-Based Conference Series

Evolution of Ferment conference to kick off Summer 2025BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference SeriesEach Ferment in the 2025 series will dive deep into specific focus areas—spanning Ginkgo's cell engineering and biosecurity offerings—and highlight how Ginkgo's broad horizontal platform for engineering biology is enabling transformative solutions across markets including pharma & biotech, agriculture, industrial biotech, government, and beyond. Speawkers and panelists will include Ginkgo experts, partners, and industry leaders who are applying engineered biology to discover, optimize, and manufacture cutting-edge products.Attendees will also get a close look at Ginkgo's technologies and the innovations they have delivered to partners around the world. In addition, entirely new products and next-generation services will be showcased, including Ginkgo Datapoints' high-throughput AI-driven data generation services; Ginkgo Automation's Reconfigurable Automation Cart (RAC) systems; and Ginkgo Biosecurity's product suite anchored by Canopy (persistent, environmental pathogen monitoring) and Horizon (data-driven global threat intelligence)."We made big changes in 2024, and our mission is stronger than ever," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Whether you're seeking the perfect antibody, looking to spin up a data generation engine to train your biological AI model, outfitting your lab with extensible and flexible automation, or building a new biosecurity solution to meet your mission's demands, you can find your needle in our tech stack

PR Newswire
Jan 23rd, 2025
Ginkgo Automation To Deploy Flexible Laboratory Automation System For Cutting-Edge Biofuels And Bioproducts Research At Great Lakes Bioenergy Research Center (Glbrc)

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass

PR Newswire
Jan 13th, 2025
Ginkgo Bioworks Partners With Universal Cells, An Astellas Company, To Advance Next-Generation Ipsc-Derived Cell Therapies For Solid Tumors

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeuticsBOSTON, Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.iPSC-derived cell therapies have the potential to transform cancer care by offering scalable, 'off-the-shelf' treatment options. However, bringing efficacious therapies to patients requires robust design and screening processes to improve persistence in the patient to enable durable clinical responses. By combining Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in design and screening large CAR libraries and its high throughput, multimodal immune cell engineering platform, the companies aim to accelerate the development of more potent and durable cell therapies while maintaining manufacturability at scale.Ginkgo's approach leverages computational tools, deep expertise in library assembly and screening, and rigorous statistical analysis and biological insight to help partners discover and engineer optimal therapeutic designs with greater speed and precision. Ginkgo's platform capabilities extend across multiple dimensions of cell therapy development, including chimeric antigen receptor (CAR) discovery and optimization, armoring strategies for enhanced cell survival and persistence, and gene editing tools for immune cell engineering

Stock Titan
Jan 9th, 2025
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks (NYSE: DNA), a company focused on cell programming and biosecurity, announced that its Co-Founder and CEO Jason Kelly will present at the 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire
Dec 17th, 2024
Ginkgo Bioworks Awarded $9.4 Million In Partnership With Carnegie Mellon University To Develop Implantable Cell-Based Bioelectronic Devices For Disease Treatment Under Arpa-H'S React Program

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disordersBOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. Ginkgo is eligible to receive up to $9.4 million for its work across the program.Chronic diseases that require continuous monitoring and treatment, such as thyroid disorders, diabetes, and obesity affect millions globally, presenting a significant public health challenge. Through this collaboration, Ginkgo will leverage its industry-leading capabilities in mammalian cell engineering and induced pluripotent stem cell (iPSC) engineering to create cells that produce and deliver therapeutic molecules—such as hormones—and/or monitor the disease status.The Biointegrated Implantable Systems for Cell-based Sensing and Therapy (BIO-INSYNC) project focuses on implantable bioelectronic devices that utilize engineered cells to produce therapeutic molecules on demand and/or to measure disease biomarkers in real time. These devices are expected to function for at least a year after implantation